1. Introduction {#sec1}
===============

Growth hormone (GH) signaling plays a major role in regulating body composition and glucose metabolism [@bib1]. Increased protein accretion in muscle and lipolysis in adipose tissue are biological consequences of GH action and together promote a lean phenotype [@bib2]. Despite its ability to improve body composition, GH has also been described as a diabetogenic agent with the ability to increase hepatic glucose production [@bib3]. Nevertheless, clinical trials using GH therapy to treat patients with obesity and type 2 diabetes demonstrated improvements in body composition, glucose tolerance, and insulin sensitivity [@bib4], [@bib5].

In both human and mouse brain, GH and the GH receptor (GHR) are present in regions known to participate in the regulation of feeding behavior, energy balance, and glucose metabolism such as the hypothalamus, hippocampus, and amygdala [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]. Upon GHR activation, the signal transducer and activator of transcription 5 (Stat5) is recruited and regulates the transcription of genes directly controlled by GH [@bib11], [@bib12]. In the arcuate nucleus of the hypothalamus (ARH), GHR is involved in the negative feedback loops that regulate GH production and secretion from somatotrophs of the pituitary [@bib7]. Systemic administration of GH induces expression of the c-fos gene, a marker of neuronal activity, on the hypothalamic neuropeptide Y (NPY) and somatostatin neurons [@bib13]. The majority of NPY mRNA-containing cells in the ARH express the GHR gene, suggesting that NPY neurons in the ARH mediate the feedback effect of GH on the hypothalamus. Feedback inhibition of GH production is predicated upon proper function of the GHR signaling cascade [@bib14].

Long-lived GH receptor (GHR) knockout mice (GHR^−/−^) are obese, with elevated leptin levels and increased insulin sensitivity [@bib15]. Deletion of hypothalamic GH-releasing hormone (GHRH) leads to isolated GH deficiency and increases lifespan, while overexpression of GH in the CNS results in hyperphagia-induced obesity, highlighting the importance of GH signals in hypothalamic neurons [@bib16], [@bib17]. In contrast, mice with modest increases in GH levels show improvements in glucose homeostasis with minimum effects on adiposity [@bib18]. We recently reported that GHR^−/−^ mice have reduced formation of both orexigenic and anorexigenic hypothalamic projections, while disruption of GHR specifically in liver, a mutation that reduces circulating IGF1, had no effect on hypothalamic development [@bib19]. While some suggest that CNS effects of GH signaling are indirect, via increases in circulating IGF1 [@bib20], these data show that GHR has a direct effect on the CNS; however, the precise role of GHR in hypothalamic neurons remains largely unknown.

Nutrient sensing, leptin receptor expressing (LepRb) neurons sense and integrate signals relevant to nutrient homeostasis to control energy balance and metabolism [@bib21]. Previous studies also indicate that leptin can modulate GH secretion and the GH response to GHRH [@bib22]. LepRb neurons are widely distributed within the hypothalamic ARH, VMH, DMH, LHA, and some additional sites that also express GHR [@bib10], [@bib23]. Recent transcriptome analysis of LepRb expressing neurons revealed that the *Ghr* gene is strongly enriched in LepRb neurons [@bib24].

Given the crucial role of LepRb neurons in the regulation of energy and glucose metabolism, along with potential overlap between LepRb and GH-responsive cells, we hypothesized that LepRb neurons represent an important site for GH signaling to control metabolism. We therefore deleted GHR specifically in LepRb neurons and examined parameters of energy homeostasis and glucose metabolism in these mice.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

*GHR*^*L/L*^ and *Lepr*^*cre*^ mice on the ROSA26 background were described previously [@bib21], [@bib25]. Mice were bred in our colony at the University of Michigan. Procedures involved in this study were approved by the University of Michigan Committee on the Use and Care of Animals (IACUC). Animals were fed breeder chow diet containing 5 kcal %fat or high fat diet containing 45 kcal %fat (Research Diets, Inc). Most of the presented data relates to male mice, unless otherwise stated.

2.2. Metabolic analysis {#sec2.2}
-----------------------

Lean and fat body mass were assessed by a Bruker Minispec LF 90II NMR-based device. Blood glucose levels were measured on random-fed or overnight-fasted animals in mouse-tail blood using Glucometer Elite (Bayer). Intraperitoneal glucose tolerance tests were performed on mice fasted for 16 h overnight. Animals were then injected intraperitoneally with [d]{.smallcaps}-glucose (2 g/kg), and blood glucose levels were measured as before [@bib26]. For an insulin tolerance test, animals fasted for 5 h received an intraperitoneal injection of human insulin (0.5 units/kg; Novo Nordisk). Blood insulin and leptin levels were determined on serum from tail vein bleeds using a Rat Insulin ELISA kit and Mouse Leptin ELISA kit (Crystal Chem. Inc.). For food intake measurements mice were singly housed and food intake was measured for 6 consecutive days. Plasma Triglycerides, Low Density Lipo-protein (LDL) and Free Fatty Acids were assessed using spectrophotometric assay kits purchased from Wako Diagnostics (Richmond, VA).

For peripheral leptin stimulation, mice were treated with either 5 mg/kg recombinant mouse leptin (provided by Dr. A Parlow, National Hormone and Pituitary Program, Torrance, CA) or vehicle, injected i.p. and perfused 2 h later. For peripheral GH stimulation (12.5 μg/100 g BW, GroPep Bioreagents Pty Ltd, Australia), mice were injected i.p and perfused 1.5 h later.

2.3. Western blotting {#sec2.3}
---------------------

Male mice were fasted overnight (18 h). For insulin stimulation, human insulin (5 U) was injected through the inferior vena cava. Liver was dissected and immediately frozen in liquid nitrogen after 5 min of insulin stimulation. For immunoprecipitation, liver extracts were incubated with rabbit polyclonal antibodies against Irs1 for 3 h at 4 °C on a rocker. Then protein A-Sepharose was added and incubated for 1 h at 4 °C. Phosphorylated or total protein was analyzed by immunoblotting with specific antibodies against Irs1 and phosphotyrosine (Millipore). Phosphorylated or total Akt were analyzed by immunoblotting with specific antibodies (Cell Signaling Technology).

2.4. Hyperinsulinemic-euglycemic clamp {#sec2.4}
--------------------------------------

At 14 weeks of age, the right jugular vein and carotid artery were surgically catheterized, and male mice were given 5 days to recover from the surgery. After 5--6 h fast, hyperinsulinemic-euglycemic clamp studies were performed on unrestrained, conscious mice by the University of Michigan Animal Phenotyping Core using the protocol adopted from the Vanderbilt Mouse Metabolic Phenotyping Center [@bib27], consisting of a 90-min equilibration period followed by a 120-min experimental period (t = 0--120 min). Insulin was infused at 2.5 mU/kg/min. To estimate insulin-stimulated glucose uptake in individual tissues, a bolus injection of 2-\[1-14C\]deoxyglucose (PerkinElmer Life Sciences) (10 μCi) was given at t = 78 min while continuously maintaining the hyperinsulinemic-euglycemic steady state. At the end of the experiment, animals were anesthetized with an intravenous infusion of sodium pentobarbital, and tissues were collected and immediately frozen in liquid nitrogen for later analysis of tissue 14C radioactivity. Plasma insulin was measured using the Millipore rat/mouse insulin ELISA kits. For determination of plasma radioactivity of \[3-3H\]-glucose and 2-\[1-14C\] deoxyglucose, plasma samples were deproteinized and counted using a liquid scintillation counter. For analysis of tissue 2-\[1-14C\] deoxyglucose 6-phosphate, tissues were homogenized in 0.5% perchloric acid, and the supernatants were neutralized with KOH. Aliquots of the neutralized supernatant with and without deproteinization were counted for determination of the content of 2-\[1-14C\] deoxyglucose phosphate.

2.5. RNA extraction and qPCR {#sec2.5}
----------------------------

Hypothalami were carefully dissected using Brain Matrices (Braintree Scientific, Braintree, MA). Isolated mRNA from this tissue was analyzed using quantitative real-time PCR. RNA was isolated using the QIAGEN RNeasy Kit (QIAGEN, Valencia, CA), which was combined with the RNase-Free DNase Set (QIAGEN, Valencia, CA). Total RNA was extracted from tissues with Trizol (Gibco BRL) and reverse transcribed using iscript cDNA kit (Bio-Rad Laboratories Inc.). Relative expression of target mRNAs was adjusted for total RNA content by beta-actin RNA quantitative PCR. Quantitative PCR was performed on an ABI-PRISM 7900 HT Sequence Detection system (Applied Biosystems, Foster City, CA). Each reaction was carried out in triplicate as previously described [@bib28]. Primers used including the following: *AgRP* F: AGGGCA TCAGAAGGCCTGACCA, *AgRP* R: CTTGAAGAAGCGGCAGTAGCAC, *POMC* F: AAGAGCAGTGACTAAGAGAGGCCA, *POMC* R: ACATCTATGGAGGTCTGAAGCAGG, *NPY* F: TAGGTAACAAACGAATGG GG, *NPY* R: AGG ATGAGATGAGATGTGGG, *LepRb* R: GGAGACAGAGGCCCAGACATT, *LepRb* F: AAACTTCCCTCCAGTTCCAAAAG-3, *GHR* R: GCGCTGAACTGGACCCTGCTGAAT, *GHR* F: GGGGGTCTGGACTGGGGAGCTG, *IGF-1* R: TCGCATCTCTTCTATCTGGCCCTGT, *IGF-1* F: GCAGTACATCTCCAGCCTCCTCAGA, *G6Pc* F: GGCTCACTTTCCCCATCAGG, *G6Pc* R: ATCCAAGTGCGAAACCAAACAG, *Pck1* F: CCCACTGGGAACACAAACTT, *Pck1* R: CCTTTCTTCTCTTTGGATGATCT.

2.6. Perfusion and histology {#sec2.6}
----------------------------

Male mice were anesthetized (IP) with avertin and transcardially perfused with phosphate-buffered saline (PBS) (pH 7.5) followed by 4% paraformaldehyde (PFA). Brains were post-fixed, sank in 30% sucrose, frozen in OCT medium, and then sectioned coronally (30 μm) using a Leica 3050S cryostat. Six series were collected and stored at −20 °C in cryoprotectant, until processed for immunohistochemistry as previously described [@bib19], [@bib29]. For immunohistochemistry, free-floating brain sections were washed in PBS, blocked using 3% normal donkey serum (NDS) and .3% Triton X-100 in PBS and then stained with primary overnight in blocking buffer. For pStat3 and pStat5 immunostaining, sections were pretreated for 20 min in 0.5% NaOH and 0.5% H~2~O~2~ in potassium PBS, followed by immersion in 0.3% glycine for 10 min. Sections were then placed in 0.03% SDS for 10 min and placed in 4% normal serum plus 0.4% Triton X-100 plus 1% BSA for 20 min before incubation for 24 h with a rabbit anti-pStat3 antibody (1:1000; Cell Signaling Technology, Danvers, MA) or a rabbit anti-pStat5 antibody (1:1000; Cell Signaling Technology, Danvers, MA). Sections were mounted onto Superfrost Plus slides (Fisher Scientific, Hudson, NH) and cover slips added with ProLong Antifade mounting medium (Invitrogen, Carlsbad, CA). Microscopic images were obtained using an Olympus Fluoview 500 Laser Scanning Confocal Microscope (Olympus, Center Valley, PA) equipped with a 20× objective.

2.7. Double-label in situ hybridization/immunohistochemistry {#sec2.7}
------------------------------------------------------------

Double-label ISH and immunohistochemistry (IHC) was performed as previously described [@bib30], [@bib31]. Briefly, free-floating sections from control and deleted mice (n = 3/group) were rinsed in DEPC-treated PBS and treated with 0.1% sodium borohydride for 15 min. Sections were treated with 0.25% acetic anhydride in 0.1 M triethanolamine (TEA, pH 8.0) for 10 min then washed in 2 × SSC. The GHR riboprobe (847 bp of size) was generated from ARH cDNA using T3 CAGAGATGCAATTAACCCT CACTAAAGGGAGACCAAGTGTCGTTCCCCTGAA and T7 CCAAGCCTT CTAATACGACTCACTATAGGGAGACTTTGGAACTGGGACTGGGG primers. The ^35^S-labeled GHR riboprobe was diluted to 10^6^ cpm/mL in a hybridization solution containing 50% formamide, 10 mM Tris--HCl (pH 8.0), 5 mg tRNA (Invitrogen), 10 mM dithiotreitol (DTT), 10% dextran sulfate, 0.3 M NaCl, 1 mM EDTA, and 1 × Denhardt\'s solution. The sections were incubated overnight at 50 °C in the hybridization solution containing the riboprobe. Subsequently, sections were treated with RNase A, submitted to stringency washes in SSC, and incubated in anti-GFP (1:5,000; Aves Labs) overnight at room temperature. The next day, sections were incubated for 1.5 h in secondary antibody (biotin-conjugated donkey anti-chicken, 1:1,000, Jackson Labs) and for 1 h in biotin-avidin complex (1:500, Vector Labs). Peroxidase reaction was performed using 3, 3′-diaminobenzidine tetrahydrochloride (DAB; Sigma) as chromogen, and sections were mounted onto SuperFrost plus slides and dried overnight at room temperature. Tissue was dehydrated in increasing concentrations of ethanol and slides were placed in X-ray film cassettes with BMR-2 film (Kodak) for 2 days and then dipped in NTB-2 autoradiographic emulsion (Kodak), dried, and stored in light-protected boxes at 4 °C for 2 weeks. Finally, slides were developed with D-19 developer (Kodak), dehydrated in graded ethanol, cleared in xylenes, and coverslipped with Permaslip.

2.8. Images and data analysis {#sec2.8}
-----------------------------

All sections used for ISH/IHC were visualized with a Zeiss M2 microscope. Photomicrographs were produced by capturing images with a digital camera (Axiocam, Zeiss) mounted directly on the microscope using the Zen software. Cells were considered dual labeled if the density of silver grains overlying the cytoplasm (GFP-IR) of the cell was at least 3× greater than the background level. Only one representative section and one side of the brain was counted per mouse per group; therefore, no correction for double counting was used. Adobe Photoshop CS6 image-editing software was used to integrate photomicrographs into plates. Only sharpness, contrast and brightness were adjusted.

2.9. Statistical analysis {#sec2.9}
-------------------------

Unless otherwise stated, mean values ± SEM are presented in graphics, and significance was determined by a Student\'s *t*-test. A p-value less than 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Generation of Lepr^EYFPΔGHR^-mice {#sec3.1}
--------------------------------------

To inactivate GHR specifically in leptin receptor expressing neurons (LepRb), we crossed Lepr^cre^ on the cre-inducible ROSA26-EYFP background together with GHR^l/l^ mice, in which the GHR coding sequence was surrounded by LoxP sites [@bib21]. Lepr^EYFPΔGHR^-mice are born at the expected Mendelian ratio and are of normal size and appearance. To determine the potential neuronal groups where GHR and LepRb converge, we performed dual in situ hybridization (ISHH) for GHR and immunohistochemistry (IHC) for GFP on the same coronal brain sections of LepRb^EYFP^ and Lepr^EYFPΔGHR^-mice. The LepRb neurons were revealed by the expression of GFP. The percentage of dual-labeled cells for both GFP-IR and GHR mRNA expression in LepRb^EYFP^ and Lepr^EYFPΔGHR^ include ARH, DMH and LHA neurons ([Figure 1](#fig1){ref-type="fig"}A, B and [Suppl. Figure 1A](#appsec1){ref-type="sec"}).

Consistent with restricted inactivation of the GHR in defined subpopulations of LepRb hypothalamic neurons, qPCR analysis revealed no alterations in overall hypothalamic GHR gene expression ([Figure 1](#fig1){ref-type="fig"}C). Similarly, GHR expression in peripheral tissues including liver, muscle, pancreas, and pituitary remained unchanged in Lepr^EYFPΔGHR^-mice ([Figure 1](#fig1){ref-type="fig"}C).

Furthermore, serum IGF-1 and GH levels were not significantly different between Lepr^EYFPΔGHR^ and controls ([Suppl. Figure 1B, C](#appsec1){ref-type="sec"}), and IGF1 mRNA levels in liver were similar in Lepr^EYFPΔGHR^ and control mice ([Figure 1](#fig1){ref-type="fig"}D).

GH has been shown to activate several intracellular signaling pathways, including the JAK/Stat5 pathway [@bib32], [@bib33]. Cells that exhibit pStat5-immunoreactivity after an acute GH stimulus are considered to be GH responsive [@bib11]. We next determined the functional effects of LepRb neuron-restricted GHR deficiency on GH ability to activate the Stat5 pathway in control Lepr^EYFP^ and Lepr^EYFPΔGHR^-mice. In the basal state, about 10% of the ARH LepRb neurons contained immunoreactive pStat5 in fasted control and Lepr^EYFPΔGHR^-mice ([Figure 2](#fig2){ref-type="fig"}). Acute intraperitoneal GH treatment significantly induced pStat5 in control mice. By contrast, GH treatment of Lepr^EYFPΔGHR^ mice showed a significantly lower percentage of ARH LepRb neurons containing pStat5-IR cells ([Figure 2](#fig2){ref-type="fig"}). As a measure of LepRb signaling [@bib21], we measured leptin-stimulated accumulation of pStat3 in the hypothalamus of Lepr^EYFPΔGHR^-mice. We found that acute leptin treatment promotes similar levels of hypothalamic pStat3 in control and Lepr^EYFPΔGHR^ mice; demonstrating that LepRb-Stat3 signaling was not impaired in Lepr^EYFPΔGHR^ mice ([Suppl. Figure 2](#appsec1){ref-type="sec"}).

3.2. Normal body weight in Lepr^EYFPΔGHR^-mice {#sec3.2}
----------------------------------------------

To assess the impact of GHR deletion in LepRb neurons on energy balance, we compared body weight and body composition of control and Lepr^EYFPΔGHR^ male mice. Lepr^EYFPΔGHR^-mice displayed no alterations in body weight relative to controls between 4 and 24 weeks of age ([Figure 3](#fig3){ref-type="fig"}A), and both genotypes responded to high-fat diet (HFD) with similar increases in weight gain ([Suppl. Figure 5A](#appsec1){ref-type="sec"}).

Consistent with these findings, circulating serum leptin and adiponectin concentrations were indistinguishable between control and Lepr^EYFPΔGHR^ male mice on chow diet and increased to the same extent on HFD ([Figure 3](#fig3){ref-type="fig"}D and [Suppl. Figure. 3 and 5D](#appsec1){ref-type="sec"}). Similarly, fat and lean body mass on both chow and HFD were comparable between groups ([Figure 3](#appsec1){ref-type="sec"}B, C and [Suppl. Figure 5B, C](#appsec1){ref-type="sec"}). Furthermore, Lepr^EYFPΔGHR^ mice showed food intake similar to control male mice ([Figure 3](#fig3){ref-type="fig"}E). Body length was indistinguishable between control and Lepr^EYFPΔGHR^ mice, a further indication of the intact function of the growth pathway despite the absence of GHR signaling in LepRb neurons (data not shown). Body weight, serum levels of leptin, and GH and IGF1 concentrations were also unaltered in female mice ([Suppl. Figure 4](#appsec1){ref-type="sec"} and data not shown). Expression of anorexigenic neuropeptides (e.g., POMC) and orexigenic neuropeptides (such as NPY and AgRP) did not differ between Lepr^EYFPΔGHR^ mice and control male mice ([Figure 3](#fig3){ref-type="fig"}F). Taken together, these data indicate that energy homeostasis in mice is unaffected by selective, targeted disruption of the GHR gene in LepRb neurons.

3.3. Lepr^EYFPΔGHR^-mice exhibit impaired glucose homeostasis and fail to suppress hepatic glucose production {#sec3.3}
-------------------------------------------------------------------------------------------------------------

Next we investigated glucose homeostasis in Lepr^EYFPΔGHR^ male mice. Basal blood glucose and serum insulin concentrations were indistinguishable between Lepr^EYFPΔGHR^ mice as compared to controls ([Figure 4](#fig4){ref-type="fig"}A--C). Despite normal fasting glucose levels, Lepr^EYFPΔGHR^ mice displayed significant glucose intolerance in response to an intraperitoneal glucose load on both chow and HFD ([Figure 4](#fig4){ref-type="fig"}A, D). Insulin tolerance was subsequently tested to determine whether this glucose intolerance was associated with systemic insulin resistance. However, the glucose-lowering effect of insulin and the rate of glucose disappearance (calculated as the slope from time 0 to 30) during the insulin tolerance test (ITT) were similar in both groups ([Figure 4](#fig4){ref-type="fig"}E, F). Insulin tolerance also did not differ between control and Lepr^EYFPΔGHR^ mice after 10 weeks on the HFD (data not shown). To assess the contribution of individual tissues to glucose metabolism, we performed a hyperinsulinemic-euglycemic clamp on Lepr^EYFPΔGHR^ and control mice at 14--16 weeks of age. Clamp studies allow for an accurate determination of insulin-dependent peripheral glucose uptake and liver glucose output *in vivo* [@bib27]. During the clamp, the glucose infusion rate required to maintain euglycemia was significantly reduced in Lepr^EYFPΔGHR^ compared to control mice (p \< 0.002) ([Figure 5](#fig5){ref-type="fig"}A, B). Under basal conditions, whole-body glucose utilization, equivalent to endogenous hepatic glucose production (HGP), did not differ between control and Lepr^EYFPΔGHR^ mice ([Figure 5](#fig5){ref-type="fig"}C and [Suppl. Figure 6](#appsec1){ref-type="sec"}). The major difference in glucose turnover rate between the groups came during clamp conditions when HGP was reduced to a greater extent in control (64%) vs. Lepr^EYFPΔGHR^ (25%) (p \< 0.005) ([Figure 5](#fig5){ref-type="fig"}D). Steady-state serum insulin levels, whole body glucose clearance, and glycolysis were indistinguishable between control and Lepr^EYFPΔGHR^ mice ([Figure 5](#fig5){ref-type="fig"}E and [Suppl. Figure 6](#appsec1){ref-type="sec"}). Determination of tissue-specific glucose uptake rates showed similar rates of insulin-stimulated glucose uptake in skeletal muscle and adipose tissue in both groups of mice ([Figure 5](#fig5){ref-type="fig"}F). These data demonstrate that the observed whole-body glucose intolerance in Lepr^EYFPΔGHR^ mice is driven mainly by changes in hepatic gluconeogenesis rather than by changes in glucose uptake by peripheral tissue.

The levels of basal free fatty acids (FFAs) were not significantly different between control and Lepr^EYFPΔGHR^ mice ([Figure 6](#fig6){ref-type="fig"}A). During the clamp, insulin-induced suppression of plasma FFA concentrations was less in Lepr^EYFPΔGHR^ mice ([Figure 6](#fig6){ref-type="fig"}A), suggesting an impairment in the ability of insulin to suppress lipolysis in these mice. Fasted triglyceride (TG) levels were not significantly different between the control (GHR^fl/fl^ 107.6 ± 21.2), and Lepr^EYFPΔGHR^ (86.9 ± 12.35 mg/dL) mice ([Suppl. Figure 7A](#appsec1){ref-type="sec"}), and expression of *ACC1*, *FASN*, *SREBP-2* and *SREBP-1c* was unaltered ([Suppl. Figure 7C](#appsec1){ref-type="sec"}). In contrast, fasted LDL levels were significantly increased in the Lepr^EYFPΔGHR^ vs. control mice (GHR^fl/fl^ 28.8.6 ± 1.77, and Lepr^EYFPΔGHR^ 41.02 ± 2.94 mg/dL) ([Suppl. Figure 7B](#appsec1){ref-type="sec"}), Together these findings indicate that loss of GHR in LepR-b neurons affects central regulation of HGP and also influences peripheral lipid metabolism.

To determine whether insulin regulation of hepatic expression of key gluconeogenic genes was intact, real-time PCR was performed in livers from fasted animals and following the hyperinsulinemic-euglycemic clamp. Clamp steady-state expression of the glucose-6-phosphatase protein (G6Pase) and phosphoenolpyruvate carboxykinase 1 (Pck1) was significantly greater in liver of Lepr^EYFPΔGHR^ mice than in control mice (*p* \< 0.05) ([Figure 6](#fig6){ref-type="fig"}B). Prior to the hyperinsulinemic clamp procedure, the basal levels of *G6Pase*, and *Pck1* were comparable in both groups (data not shown).

3.4. Hepatic signaling in Lepr^EYFPΔGHR^-mice {#sec3.4}
---------------------------------------------

To explore the molecular basis for reduced hepatic insulin sensitivity, we next determined whether this effect was associated with impaired insulin signal transduction in the livers of Lepr^EYFPΔGHR^ mice. To test this possibility, we examined the levels of phosphorylation of two key components in the insulin signaling pathways [@bib34], insulin receptor substrate 1 (IRS-1) and protein kinase B (Akt), in liver after i.v. injection of insulin, as described previously [@bib26]. As shown in [Figure 7](#fig7){ref-type="fig"}A, B, insulin-stimulated phosphorylation of IRS-1 was significantly attenuated in the liver of Lepr^EYFPΔGHR^ mice. Consistent with these results, insulin-stimulated Akt^Ser473^ phosphorylation was significantly reduced in the liver of Lepr^EYFPΔGHR^ mice as compared with control mice (*p* \< 0.05) ([Figure 7](#fig7){ref-type="fig"}C), and further supports the induction of hepatic insulin resistance in this model.

4. Discussion {#sec4}
=============

We have generated a new mouse model to dissect the role of CNS GHR signaling in LepRb expressing neurons. Our results identify for the first time a population of neurons responsible for the hypothalamic actions of GHR on hepatic glucose production (HGP). Specifically, loss of GHR in LepRb-expressing neurons of the ARH, DMH and LHA impairs the ability of insulin to regulate HGP and peripheral lipid metabolism. Importantly, these effects are mediated via mechanisms that are independent of hormonal changes or body adiposity.

Recent analysis of the distribution of GH-responsive cells revealed the abundance of GH-responsive neurons in hypothalamic nuclei involved in the control of metabolism, such as the ARH, VMH, and DMH. This suggests that central GH signaling might be involved in energy expenditure and glucose homeostasis through a central mechanism [@bib10]. GH overexpression in the CNS results in hyperphagia-induced obesity, insulin resistance, and increased circulating GH levels [@bib17]. Additional studies reported obesity after expressing GH and GH-releasing hormone in the CNS, which has been attributed to lowering of endogenous GH levels [@bib35], [@bib36]. However, these animal models did not dissect the effect of GH signaling in specifically defined neurons in the CNS, since they utilized CNS-wide promoters and had confounding effect of chronically altered GH levels. In contrast, we show that specific deletion of GHR signaling in LepRb neurons impairs insulin\'s ability to suppress hepatic glucose production independent of changes in IGF-1 or GH circulating levels. Moreover, LepRb neuron-restricted inactivation of the GHR does not interfere with the regulation of food intake or energy homeostasis under normal conditions or under high-fat diet, thus allowing determination of direct effects of central GHR signals on other tissues.

Decreases in glucose levels are detected by glucose-sensing neurons that are found in several brain regions including the VMH, the LHA, the ARH, as well as in several hindbrain regions [@bib37], [@bib38]. GH release contributes to glucose counter-regulation by shifting metabolism of non-neural tissues away from glucose utilization [@bib39]. Hypothalamic GH releasing hormone (GHRH) neurons are glucose responsive, increasing activity in response to decreasing glucose levels [@bib40]. However, the direct actions of GH are mediated through GHR [@bib5], and very few GHRH neurons express GHR [@bib41]. LepRb neurons regulate glucose homeostasis, and our data show that they co-express GHR in the ARH, DMH, and LHA neurons. Lean Lepr^EYFPΔGHR^ mice are not GH deficient but are hyperglycemic after a glucose load and have impaired HGP and lipid metabolism. Thus, one may speculate that the GHR in hypothalamic LepRb neuronal subsets of the ARH, DMH, and LHA directly or indirectly facilitates insulin signaling. Cell-type specific ablation of GHR will be necessary to unravel the functional significance of GHR expressing neurons in controlling glucose metabolism independently of body weight.

Hepatic gluconeogenesis is a major contributing factor to hyperglycemia [@bib42], and GH is reported to enhance hepatic gluconeogenesis [@bib43]. This mechanism cannot explain impaired HGP in Lepr^EYFPΔGHR^ mice, since they have normal GH and IGF-1 levels. Consistent with the marked increase of HGP, insulin-induced suppression of hepatic gluconeogenic genes *G6Pase* and *Pck1* expression is blunted and hepatic insulin signaling reduced, indicating that increased hepatic gluconeogenesis and impaired insulin signaling contributed to hyperglycemia provoked by deleting GHR from specific LepRb neuronal subsets. We cannot, however, rule out the possibility that reduced hepatic insulin signaling is a secondary effect [@bib44], since Lepr^EYFPΔGHR^ mice are not insulin resistant. The ability of insulin to decrease plasma fatty acid concentrations during the hyperinsulinemic-euglycemic clamp was also reduced in Lepr^EYFPΔGHR^ mice, suggesting that insulin suppression of lipolysis was impaired, which might contribute to hepatic insulin resistance through direct or indirect generation of metabolites that alter the insulin-signaling cascade [@bib45]. Increased plasma total cholesterol levels in Lepr^EYFPΔGHR^ mice also can be attributed to increased cholesterol uptake and export from the liver. Further studies will be necessary to determine the effects of GHR-LepRb neuronal subsets on lipid metabolism and the interaction with other hormones that regulate HGP.

HGP can be stimulated by increased activity of the sympathetic input to the liver or decreased activity of the parasympathetic input to the liver [@bib46], [@bib47]. The parasympathetic tone in rats might be physiologically relevant in controlling the basal HGP [@bib48]. Vagus nerve innervation is important in mediating brain insulin control of hepatic glucose homeostasis [@bib49]. Proper functioning of the vagus nerve is important for production of GHRH and IGF-1 [@bib50]. It is reasonable to hypothesize that vagus nerve innervations are involved in central GHR signaling effect on glucose metabolism. The sympathetic nervous system (SNS) has been implicated in leptin actions [@bib51], and in central insulin mediated lipogenesis [@bib52]. Additional studies will be necessary to delineate the role of the two branches of the autonomic nervous system in the central GHR-mediated HGP.

It has been shown previously that hypothalamic leptin and insulin signaling are required for the inhibition of HGP [@bib53], [@bib54], [@bib55], [@bib56]. Indeed, intracerebroventricular infusion of insulin or leptin in rodents can potently suppress hepatic glucose production, whereas antagonism of insulin or leptin signaling in the hypothalamus can impair the ability of peripheral insulin to suppress HGP [@bib55], [@bib56]. Evidence suggests that NPY neurons are involved in this process [@bib57]. Interestingly, increased CNS NPY signaling can modulate hepatic lipoprotein metabolism [@bib58]. The majority of neuropeptide Y (NPY) neurons in the ARH co-express GHR and LepRb [@bib59], and NPY neurons mediate the feedback effect of GH on the hypothalamus [@bib13]. The functional significance of GH signals on NPY neurons remains somewhat undefined [@bib60]. Thus it is possible to speculate that NPY- LepRb neuronal circuitry is involved in the physiology of GHR responses, and might regulate its function.

Previous studies indicate that LepRb-DMH neurons strongly connect to the PVH [@bib61], and PVH regulates glucose homeostasis, probably via the sympathetic nervous system (SNS)-liver axis [@bib62], thus suggesting a role for the DMH in glucose metabolism. Conversely, while it is unlikely that LepRb-LHA neurons mediate leptin\'s anti-diabetic actions in the regulation of glucose homeostasis [@bib63], [@bib64], it can still be speculated that LepRb-LHA neurons provide an essential output for autonomic responses, since a significant subpopulation of LHA neurons are glucose inhibited [@bib65], and their role in GH responses or GHR signaling is unclear. Future identification of these GHR-LepRb neuronal subsets will be required to understand how these are controlled differentially and to determine the respective roles of these neuronal populations and their hypothalamic circuitry in the control of glucose metabolism.

Leptin signaling may be important in the maintenance of somatotropes, acting directly at the level of the pituitary [@bib66]. Interestingly, somatotrope-specific Lepr knockouts showed reduced serum GH and increased fat mass and impaired Stat3 signaling, demonstrating the importance of leptin in the direct regulation of somatotrope function [@bib67]. We and others did not detect expression of Lepr-cre in pituitary (data not shown), and the expression of GHR in the pituitaries of Lepr^EYFPΔGHR^ mice was intact. Furthermore, deletion of GHR from LepRb neurons had no effect on Stat3 signaling or serum GH levels. In support of this idea, growth and adiposity of Lepr^EYFPΔGHR^ mice were normal.

GH secretion is consistently reduced in obesity [@bib68]. The hyperinsulinemia associated with insulin resistance in obesity has been suggested to contribute to reduced GH secretion [@bib32]. Obesity-induced leptin resistance and increased bioactive IGF-1 and FFA levels could suppress GH secretion from the pituitary by various mechanisms [@bib41]. HFD fed Lepr^EYFPΔGHR^ mice showed significantly higher glucose levels in response to an intraperitoneal glucose load as compared to control glucose intolerant mice. This data suggests that deletion of central GHR signaling in LepRb neurons might exacerbate the GH-resistant state that is associated with obesity and contribute to diet-induced obesity complications. In support, a recent study demonstrated that chronic, peripheral GH injections significantly improved glucose metabolism and reduced liver triacylglycerol content of normal HFD fed mice, suggesting an effectiveness of GH therapy in the treatment of diet-induced obesity [@bib69].

The activation of GHR induces Stat5 phosphorylation [@bib33], and cells that exhibit pStat5-immunoreactivity after an acute GH stimulation are considered to be GH responsive [@bib10]. A previous study demonstrated strong GH-induced pStat5 immunoreactive cells in the ARH, VMH, PVH, and some additional hypothalamic and extra hypothalamic areas [@bib10], [@bib70]. We detected very low GH-induced pStat5-IR cells among LepRb neurons in the Lepr^EYFPΔGHR^ mice compared to controls, indicating that GH signaling is impaired. Hypothalamic Stat5 can mediate the direct negative feedback effects by GH [@bib71]. Neuronal deletion of Stat5 results in obesity, insulin resistance, and glucose intolerance [@bib72]. LepRb specific Stat5 KO mice have normal body weight regulation [@bib73]; however, no data on the regulation of glucose metabolism was reported. Our data suggest that in specific neuronal populations, Stat5 signaling might be involved in GHR-mediated glucose homeostasis through a central mechanism.

Overall, our findings define the physiological role of GHR signaling in distinct LepRb-expressing neuronal populations. We find no role for GHR in LepRb neurons in the regulation of food intake or body weight, but our data provide powerful genetic evidence for a direct role of central GHR signals in LepRb neurons in the regulation of glucose homeostasis and hepatic glucose production. GH treatment in obese type 2 diabetes patients decreases amounts of fat and improves insulin resistance [@bib74]. We have identified LepRb-GHR neuronal populations as a crucial factor for the anti-diabetic actions of GH signaling. Understanding the molecular mechanisms operating in these neurons will yield new targets for treating obesity-driven metabolic diseases. Further identification, manipulation, and understanding of the function of specific GHR neuronal populations will be critical to address the physiological relevance of these findings for the development of metabolic diseases.
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![**Generation and validation of Lepr**^**EYFPΔGHR**^**-mice**. (A) Dual-label histochemistry was performed on coronal sections of mouse brains. Neurons with GFP-IR, which reports on LepRb expression, are stained brown. Neurons expressing GHR mRNA have overlying punctuate black silver granules. Strong co-expression of LepRb and GHR was observed in the hypothalamic ARH, DMH, and LHA (examples indicated by arrows). Co-expression in other regions of the hypothalamus was minimal. Scale bar = 50 μm. (B) Bar graph shows percent of dual-labeled cells in the ARH, DMH, and LHA in 7-week-old Lepr^EGFP^ and Lepr^EYFPΔGHR^-mice. (C) *GHR* gene expression in liver, muscle, pancreas, pituitary, and whole hypothalamus and (D) *IGF-1* gene expression in 7-week-old GHR^fl/fl^ and Lepr^EYFPΔGHR^-mice. See also [Figure S1A](#appsec1){ref-type="sec"}.](gr1){#fig1}

![**GHR signaling in Lepr**^**EYFPΔGHR**^**-mice**. (A) Immunofluorescence for pStat5 in 6-month-old Lepr^EGFP^ and Lepr^EYFPΔGHR^ mice injected IP with vehicle (saline) or GH (12.5 μg/100 g BW; 1.5 h). Representative images from the ARH of Lepr^EGFP^ and Lepr^EYFPΔGHR^ mice are shown. Scale bar: 100 μm. The lower panels are digital zooms of boxed areas from the top panel, showing pStat5 (red) merged with EGFP (green) of the indicated genotypes (examples are shown by arrows). (B) Quantification of double labeled cells \*p \< 0.05. Quantification of LepRb/EGFP neurons containing pStat5 immunoreactivity (n = 4/genotype). Data are presented as mean ± SEM; \*, p \< 0.05. See also [Figure S2](#appsec1){ref-type="sec"}.](gr2){#fig2}

![**Normal body weight in Lepr**^**EYFPΔGHR**^**-mice**. (A) Average body weights of male Lepr^EYFPΔGHR^-mice (red) and control GHR^fl/fl^-mice (blue) on regular chow diet (n = 10). (B) Percent body fat and (C) lean body mass was determined by NMR using 14-week-old GHR^fl/fl^ (n = 5--6) and Lepr^EYFPΔGHR^ (n = 5--6) mice. (D) Serum leptin levels of 14-week-old male GHR^fl/fl^ (n = 8) and Lepr^EYFPΔGHR^ (n = 8) mice. (E) Food intake was measured for 6 consecutive days in 14-week-old male GHR^fl/fl^ (n = 8) and Lepr^EYFPΔGHR^ (n = 8) mice fed regular chow diet (F). Levels of mRNA by semi-quantitative RT-PCR of *NPY*, *AgRP*, and *POMC* from hypothalamus of 14-week-old chow-fed male mice of the indicated genotypes (n = 6). Data are presented as mean ± SEM. See also [Figures. S1(B, C)--S5](#appsec1){ref-type="sec"}.](gr3){#fig3}

![**Glucose homeostasis in Lepr**^**EYFPΔGHR**^**mice**. (A) Glucose tolerance test of 16-week-old chow-fed male mice, (B) fed glucose levels (n = 10/genotype) and (C) fasting serum insulin levels (n = 10/genotype) for 16 week-old male mice of the indicated genotypes. (D) Glucose tolerance test of 24-week-old high-fat diet (HFD) fed mice of the indicated genotypes (n = 5--6/genotype). (E) Insulin tolerance test of 17-week-old mice (n = 8--10/genotype). (F) Serum glucose disappearance rate (Kitt, %/min) from the insulin tolerance test. Data are expressed as mean ± SEM. GHR^fl/fl^ mice versus Lepr^EYFPΔGHR^ -mice: \*, p \< 0.05. See also [Figure S5](#appsec1){ref-type="sec"}.](gr4){#fig4}

![**Hyperinsulinemic-euglycemic clamp in Lepr**^**EYFPΔGHR**^. (A) Blood glucose levels during the clamp period (B) Glucose infusion rates during the clamp period (p \< 0.002). (C) Hepatic glucose production (HGP) measured under basal and steady-state conditions during the clamp (p \< 0.005 for clamp). (D) Percentage suppression of HGP by insulin as measured under steady-state conditions during the clamp (p \< 0.005). (E) Steady-state serum insulin levels. (F) Tissue-specific insulin-stimulated glucose uptake rates in skeletal muscle and adipose tissue (SOL, soleus muscle; EDL, extensor digitorum longus muscle; gastroc, gastrocnemius muscle; V. Fat, visceral fat; S. Fat, subcutaneous fat), in control and Lepr^EYFPΔGHR^ male mice at 14--16 weeks of age, n = 6 mice per group. See also [Figure S6](#appsec1){ref-type="sec"}.](gr5){#fig5}

![**Levels of FFA and gluconeogenic genes under hyperinsulinemic clamp in Lepr**^**EYFPΔGHR**^: (A) The levels of free fatty acids (FFAs) at the basal level and during the clamp in 14--16 weeks old control and Lepr^EYFPΔGHR^-mice, n = 6 mice per group. (B) *G6Pc* and *Pck1* mRNA expression in liver at the end of hyperinsulinemic-euglycemic clamp in control and Lepr^EYFPΔGHR^ male mice at 14--16 weeks of age, n = 6 mice per group. Displayed values are means ± SEM, \*, p \< 0.05. See also [Figure S7](#appsec1){ref-type="sec"}.](gr6){#fig6}

![**Hepatic Insulin Signaling in Lepr**^**EYFPΔGHR**^**-mice**. Mice in each experimental group were fasted overnight and stimulated with insulin (Ins) or PBS by i.v. injection (5 min). (A) Insulin receptor substrate 1 (IRS1) level and tyrosine phosphorylation in liver extracts. Akt and its phosphorylated form (phospho-Ser473) were analyzed with specific antibodies in the liver lysates. Quantification of (B) pTyr-IRS1 and (C) pAkt. Results were normalized to loading controls and are expressed as mean ± SEM, n = 6. \*p \< 0.05 for 14-week-old control vs Lepr^EYFPΔGHR^ male mice.](gr7){#fig7}
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